Axsome Therapeutics

AXS-05 (dextromethorphan-bupropion) is a novel, oral, NMDA receptor antagonist being developed for the treatment of multiple CNS conditions. Learn more and see clinical and regulatory information.

Basic Information

Documented Facts

Evidence and Sources

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Axsome Therapeutics.

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

AXS-05 (dextromethorphan-bupropion) is a novel, oral, NMDA receptor antagonist being developed for the treatment of multiple CNS conditions. Learn more and see clinical and regulatory information.

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.